Cargando…
Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development
BACKGROUND: Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dysrhythmias. We therefore assessed the cardiovascular (CV) risk with pazopanib in...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828231/ https://www.ncbi.nlm.nih.gov/pubmed/29497565 http://dx.doi.org/10.1186/s40959-017-0024-8 |